Aspirin drug combo reduces dialysis risk
This article was originally published in The Tan Sheet
Executive Summary
Aspirin combined with the anti-platelet drug dipyridamole extends the life of artery-vein access grafts used for hemodialysis, according to a study of 649 participants with new AV grafts conducted by the Dialysis Access Consortium. The drug combination reduces loss of primary unassisted graph patency by 18 percent and the rate of developing significant stenosis by 28 percent, compared to a placebo, according to the National Institutes of Health. The release says most AVs fail because of clotting around blood vessels that narrow at the graft site